The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia-Reference-Cited by-同舟云学术

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Published:2017-05-15 Issue:13 Volume:1 Page:802-811
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Fox Lucy C.¹²,Cummins Katherine D.¹³,Costello Ben³⁴,Yeung David⁵,Cleary Rebecca⁶,Forsyth Cecily⁷,Tatarczuch Maciek⁸,Burbury Kate⁸,Motorna Olga⁹,Shortt Jake⁹¹⁰,Fleming Shaun³¹⁰,McQuillan Andrew¹¹,Schwarer Anthony¹²¹²,Harrup Rosemary¹³,Holmes Amy¹⁴,Ratnasingam Sumita¹⁵,Chan Kah-Lok¹⁶,Hsu Wei-Hsun¹⁷,Ashraf Asma¹⁸,Putt Faye¹,Grigg Andrew¹

Affiliation:

1. Austin Hospital, Melbourne, Australia;

2. Epworth Healthcare, Melbourne, Australia;

3. Alfred Hospital, Melbourne, Australia;

4. Baker IDI Heart and Diabetes Institute, Melbourne, Australia;

5. Royal Adelaide Hospital, Adelaide, Australia;

6. Princess Alexandra Hospital, Brisbane, Australia;

7. Gosford Hospital, Gosford, Australia;

8. Peter MacCallum Cancer Centre, Melbourne, Australia;

9. Monash Health, Clayton, Melbourne, Australia;

10. School of Clinical Sciences at Monash Health, Monash University, Clayton, Melbourne, Australia;

11. Hollywood Medical Centre, Perth, Australia;

12. Box Hill Hospital, Melbourne, Australia;

13. Royal Hobart Hospital, Hobart, Australia;

14. Canberra Hospital, Canberra, Australia;

15. Royal Melbourne Hospital, Melbourne, Australia;

16. St Vincent’s Hospital, Melbourne, Australia;

17. Royal Prince Alfred Hospital, Sydney, Australia; and

18. Calvary Mater Hospital, Newcastle, Australia

Abstract

Key PointsPrescribing appropriately for age and cardiovascular risk is likely to result in minimal permanent toxicity-related dasatinib cessation. CML patients on dasatinib with pleural effusion are more likely to have achieved MR4.5 after 6-month therapy than those without effusion.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/13/802/877219/advances003889.pdf

Reference33 articles.

1. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial;Cortes;J Clin Oncol,2016

2. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial;Hochhaus;Leukemia,2016

3. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events;Carneiro;Expert Rev Hematol,2015

4. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib;Hochhaus;Leukemia,2008

5. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase;Cortes;Leukemia,2008

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An association between Dasatinib, elevated left atrial pressure and pleural effusion;International Journal of Cardiology;2024-09

2. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors;Journal of the National Comprehensive Cancer Network;2024-02

3. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia;Journal of Oncology Pharmacy Practice;2023-12-17

4. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies;Current Treatment Options in Oncology;2023-12

5. The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia;Hemato;2023-07-14